Literature DB >> 11861261

Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells.

Osamu Yoshie1, Ryuichi Fujisawa, Takashi Nakayama, Hitomi Harasawa, Hideaki Tago, Dai Izawa, Kunio Hieshima, Youichi Tatsumi, Kouji Matsushima, Hitoshi Hasegawa, Akihisa Kanamaru, Shimeru Kamihira, Yasuaki Yamada.   

Abstract

Chemokines and chemokine receptors play important roles in migration and tissue localization of various lymphocyte subsets. Here, we report the highly frequent expression of CCR4 in adult T-cell leukemia (ATL) and human T-cell leukemia virus type 1 (HTLV-1)-immortalized T cells. Flow cytometric analysis revealed that ATL and HTLV-1-immortalized T-cell lines consistently expressed CCR4. Inducible expression of HTLV-1 transcriptional activator tax in a human T-cell line Jurkat did not, however, up-regulate CCR4 mRNA. In vitro immortalization of peripheral blood T cells led to preferential outgrowth of CD4(+) T cells expressing CCR4. We further demonstrated highly frequent expression of CCR4 in fresh ATL cells by (1) reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of CCR4 expression in peripheral blood mononuclear cells (PBMCs) from patients with ATL and healthy controls; (2) flow cytometric analysis of CCR4-expressing cells in PBMCs from patients with ATL and healthy controls; (3) CCR4 staining of routine blood smears from patients with ATL; and (4) an efficient migration of fresh ATL cells to the CCR4 ligands, TARC/CCL17 and MDC/CCL22, in chemotaxis assays. Furthermore, we detected strong signals for CCR4, TARC, and MDC in ATL skin lesions by RT-PCR. Collectively, most ATL cases have apparently derived from CD4(+) T cells expressing CCR4. It is now known that circulating CCR4(+) T cells are mostly polarized to Th2 and also contain essentially all skin-seeking memory T cells. Thus, HTLV-1-infected CCR4(+) T cells may have growth advantages by deviating host immune responses to Th2. CCR4 expression may also account for frequent infiltration of ATL into tissues such as skin and lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861261     DOI: 10.1182/blood.v99.5.1505

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  93 in total

1.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

Authors:  Daisuke Sugiyama; Hiroyoshi Nishikawa; Yuka Maeda; Megumi Nishioka; Atsushi Tanemura; Ichiro Katayama; Sachiko Ezoe; Yuzuru Kanakura; Eiichi Sato; Yasuo Fukumori; Julia Karbach; Elke Jäger; Shimon Sakaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

2.  Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells.

Authors:  Girish Venkataraman; Jonathan Berkowitz; John C Morris; John E Janik; Mark A Raffeld; Stefania Pittaluga
Journal:  Hum Pathol       Date:  2011-02-11       Impact factor: 3.466

Review 3.  Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.

Authors:  Waseem Lone; Aisha Alkhiniji; Jayadev Manikkam Umakanthan; Javeed Iqbal
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

4.  CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.

Authors:  Yuma Sakamoto; Keiichiro Fujii; Shunji Murase; Satsuki Nakano; Ayako Masaki; Takayuki Murase; Shigeru Kusumoto; Shinsuke Iida; Atae Utsunomiya; Ryuzo Ueda; Takashi Ishida; Hiroshi Inagaki
Journal:  Int J Hematol       Date:  2019-08-29       Impact factor: 2.490

Review 5.  Are increased Foxp3+ regulatory T cells responsible for immunosuppression during HTLV-1 infection? Case reports and review of the literature.

Authors:  Nicolas Barros; Fernando Woll; Luis Watanabe; Martin Montes
Journal:  BMJ Case Rep       Date:  2012-11-27

6.  Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.

Authors:  Kenji Ishitsuka; Mutsunori Murahashi; Hiroo Katsuya; Ai Mogi; Michio Masaki; Chisato Kawai; Toshitaka Goto; Masanao Ishizu; Yosuke Ikari; Yasushi Takamatsu; Hideki Ishibashi; Satoshi Nimura; Morishige Takeshita; Kazuo Tamura
Journal:  Int J Hematol       Date:  2015-05-21       Impact factor: 2.490

Review 7.  Molecular biology of human T cell leukemia virus.

Authors:  Lee Ratner
Journal:  Semin Diagn Pathol       Date:  2019-04-16       Impact factor: 3.464

8.  Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.

Authors:  Jun Nakashima; Yoshitaka Imaizumi; Hiroaki Taniguchi; Koji Ando; Masako Iwanaga; Hidehiro Itonaga; Shinya Sato; Yasuhi Sawayama; Tomoko Hata; Shinichiro Yoshida; Yukiyoshi Moriuchi; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2018-07-21       Impact factor: 2.490

Review 9.  Leukemogenesis of adult T-cell leukemia.

Authors:  Jun-ichirou Yasunaga; Masao Matsuoka
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

10.  Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder.

Authors:  Yoshihisa Yamano; Natsumi Araya; Tomoo Sato; Atae Utsunomiya; Kazuko Azakami; Daisuke Hasegawa; Toshihiko Izumi; Hidetoshi Fujita; Satoko Aratani; Naoko Yagishita; Ryoji Fujii; Kusuki Nishioka; Steven Jacobson; Toshihiro Nakajima
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.